Advertisement

Topics

Maas Biolab LLC Company Profile

19:00 EDT 26th March 2019 | BioPortfolio

Maas Biolab is a private pharmaceutical company in Albuquerque, N.M., USA, developing Mitogard®, the only cyclosporine formula designed for CSF delivery, to treat amyotrophic lateral sclerosis. Maas Biolab holds FDA Orphan Drug Designation for cyclosporine to treat ALS and world patents for cyclosporine neuroprotection against chronic neurological diseases. (www.maasbiolab.com).


News Articles [9 Associated News Articles listed on BioPortfolio]

Brexit deal smooths transition for MAAs, IP protections

European regulators accept MAAs for imlifidase, gilteritinib

Marketing authorization applications submitted for Hansa Biopharma's Idefirix, or imlifidase, and Astellas Pharma's Xospata,  -More- 

Collaboration And Pay For Performance Deals – The Way To Pay for One-Off Treatments

New payment models, registries and the Cross Border Healthcare Directive could help determine new ways to pay for potentially one-off...   

Avacta Agrees Affimer Reagent Licensing Deal with New England Biolab

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has agreed a commercial license with New England Biolabs® (NEB®) (Ipswi...

EMA Checklist To Help Companies Submit 'First Time Right' MAAs

A new checklist for companies from the European Medicines Agency is designed to facilitate the agency's validation of initial marketing...    

Open Cell launches shipping container labs at Shepherd's Bush Market to accelerate biotech start-up businesses

London, UK, 6th June 2018 / Sciad Newswire / Open Cell has joined forces with regeneration specialist, U+I, and the London Borough of Hammersmith and Fulham and SynbiCITE to launch a biolab to offer...

Volkswagen, Mobileye and Champion Motors to Invest in Israel and Deploy First Autonomous EV Ride-Hailing Service

NEWS HIGHLIGHTS Volkswagen Group, Mobileye and Champion Motors have announced plans to commercialize Mobility-as-a-Service (MaaS) with self-driving vehicles in Israel. Volkswagen Group will provid...

EMA launches checklist to facilitate validation for initial marketing authorisation applications

A survey launched by EMA in September 2016 shows that validation issues occur in 90% of initial marketing authorisation applications (MAAs). They create additional workload for companies and potential...

Drugs and Medications [0 Results]

None

PubMed Articles [8 Associated PubMed Articles listed on BioPortfolio]

Protective effect of MAAs extracted from Porphyra tenera against UV irradiation-induced photoaging in mouse skin.

The objective of this study was to investigate the effect of Mycosporine-like amino acids (MAAs) extracted from Porphyra tenera skin against UV irradiation-induced photoaging using an ICR mouse model ...

Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies.

Myositis-specific (MSAs) or-associated autoantibodies (MAAs) have been linked to particular clinical phenotypes of idiopathic inflammatory myopathies (IIM) and appear to aid diagnosis. The objective o...

Genetic and environmental aetiologies of associations between dispositional mindfulness and ADHD traits: a population-based twin study.

To get additional insight into the phenotype of attentional problems, we examined to what extent genetic and environmental factors explain covariation between lack of dispositional mindfulness and att...

Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.

The prevalence and diagnostic values of myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) in dermatomyositis/polymyositis (DM/PM) were studied.

Light-adaptive state transitions in the Ross Sea haptophyte Phaeocystis antarctica and in dinoflagellate cells hosting kleptoplasts derived from it.

Light state transitions (STs) is a reversible physiological process that oxygenic photosynthetic organisms use in order to minimize imbalances in the electronic excitation delivery to the reaction cen...

Clinical Trials [7 Associated Clinical Trials listed on BioPortfolio]

Biolab Zolpidem Orodispersible 1.0 mg, 1.75 mg and 3.5 mg to Treat Maintenance Insomnia Disorder.

Biolab Sanus is developing a product in the form of orodispersible tablet containing 1.0 mg, 1.75 mg and 3.5 mg of Zolpidem®. Thus, it is intended to evaluate the efficacy of Zolpidem® O...

Dietary Intervention, Gestational Weight Gain and Gestational Diabetes.

The aim of this pilot study is to conduct a dietary intervention for overweight (body maas index BMI≥25) and obese (BMI≥30) pregnant women in two maternity care clinics and explore the...

Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel

This trial evaluated folic acid supplementation after oral administration of the ethinyl estradiol + levonorgestrel + folic acid (0.02 mg + 0.10 mg + 0.4 mg) coated tablet (Level-Fol® Bio...

Androgen Responses to hCG and Ovarian Morphology in PCOS

Rationale and Hypothesis We have previously reported that theca cells (TC) responses to hCG in women with PCOS represent a spectrum where some exhibit exaggerated increases of 17OHP while ...

Market Penetration of Laser Therapy in Venous Surgery: Ziekenhuis Oost-Limburg - Ziekenhuis Maas en Kempen Center Experience

The goal of this registry is to evaluate the indication for EndoVenous Laser Ablation (EVLA) therapy. Can this be enhanced? What are the reasons for not using the laser? Therefore, this st...

Companies [9 Associated Companies listed on BioPortfolio]

Maas Biolab LLC

Maas Biolab is a private pharmaceutical company in Albuquerque, N.M., USA, developing Mitogard®, the only cyclosporine formula designed for CSF delivery, to treat amyotrophic l...

Maas Biolab, LLC

Maas Biolab is a private pharmaceutical company in Albuquerque, New Mexico, USA, developing Mitogard®, the only cyclosporin formula designed for CSF delivery, to treat amyotrop...

Maas Biolab, Inc.

Maas Biolab is a neuropharmaceutical company developing a treatment- the use of cyclosporins as neuro-protectants- for chronic neurodegenerative diseases including amyotrophic lateral sclerosis, Alzhe...

Maas Companies Inc.

Maas & Peither GMP Verlag

nil

More Information about "Maas Biolab LLC" on BioPortfolio

We have published hundreds of Maas Biolab LLC news stories on BioPortfolio along with dozens of Maas Biolab LLC Clinical Trials and PubMed Articles about Maas Biolab LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Maas Biolab LLC Companies in our database. You can also find out about relevant Maas Biolab LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record